NCT02359968 2026-03-18
PROTECT
Centre Oscar Lambret
Phase 2 Completed
Clinical Trials
68 trialsNCT03485209 2026-03-16
innovaTV 207
Seagen Inc.
Phase 2 Active not recruiting
NCT06493019 2026-03-12
Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT03174275 2026-02-23
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT07403435 2026-02-11
Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT06630325 2026-01-07
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT02297217 2025-12-16
PaRCUS
AHS Cancer Control Alberta
Phase 2 Recruiting
NCT07266493 2025-12-05
Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Shanghai Zhongshan Hospital
Phase 2 Recruiting
NCT06576973 2025-12-02
Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT05189730 2025-11-20
ETNT
Sichuan Cancer Hospital and Research Institute
Phase 2 Active not recruiting
NCT04175912 2025-11-17
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04656041 2025-11-14
Folfox+Irinotecan+Chemort In Esophageal Cancer
Massachusetts General Hospital
Phase 2 Recruiting
NCT03110926 2025-09-12
Induction Chemotherapy for Locally Advanced Esophageal Cancer
University of Rochester
Phase 2 Active not recruiting
NCT04929392 2025-09-04
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT05880082 2025-08-24
PPIO-004-EC001
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04268121 2025-07-23
NEONEC
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Recruiting
NCT07046221 2025-07-20
Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT05489211 2025-07-11
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
AstraZeneca
Phase 2 Recruiting
NCT06861894 2025-05-15
Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC
Shanghai Chest Hospital
Phase 2 Not yet recruiting
NCT06637163 2025-04-17
Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
Shanghai Zhongshan Hospital
Phase 2 Recruiting
NCT00780494 2025-01-14
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
Stanford University
Phase 2 Completed
NCT03980925 2025-01-13
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT03678883 2024-11-07
9-ING-41 in Patients with Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT05628610 2024-08-13
Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06084897 2024-06-14
Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06403878 2024-05-08
Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer
Sichuan University
Phase 2 Recruiting
NCT02931890 2024-05-02
CRITICS-II
The Netherlands Cancer Institute
Phase 2 Active not recruiting
NCT04568200 2024-01-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma
Peking Union Medical College Hospital
Phase 2 Completed
NCT02037048 2024-01-08
FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma
Case Comprehensive Cancer Center
Phase 2 Unknown
NCT02916511 2023-12-22
ESO-Shanghai9
Fudan University
Phase 2 Completed
NCT02287129 2023-11-28
MEMORI
Technical University of Munich
Phase 2 Completed
NCT04308837 2023-11-14
A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation
Icahn School of Medicine at Mount Sinai
Phase 2 Unknown
NCT06122493 2023-11-08
Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma
Ruijin Hospital
Phase 2 Recruiting
NCT05302011 2023-10-10
Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Peking Union Medical College Hospital
Phase 2 Completed
NCT06056336 2023-09-28
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
Shanghai Chest Hospital
Phase 2 Recruiting
NCT04764227 2023-08-03
Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)
Fudan University
Phase 2 Active not recruiting
NCT02560298 2023-06-22
InterAACT
Eastern Cooperative Oncology Group
Phase 2 Unknown
NCT05896787 2023-06-09
Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
The First Affiliated Hospital of Zhengzhou University
Phase 2 Not yet recruiting
NCT01333033 2023-04-13
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT05650216 2022-12-14
Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）
Shanghai Chest Hospital
Phase 2 Unknown
NCT05596890 2022-11-28
PICCRT
Guangdong Provincial People's Hospital
Phase 2 Unknown
NCT05245760 2022-11-08
CRATER
University of Kentucky
Phase 2 Withdrawn
NCT05552651 2022-09-23
Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
Air Force Military Medical University, China
Phase 2 Unknown
NCT00393068 2022-03-02
Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT05044728 2021-09-16
Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest.
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT01077999 2021-04-21
Chemoradiation and Panitumumab for Esophageal Cancer
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 2 Completed
NCT04767295 2021-02-23
A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)
Hunan Cancer Hospital
Phase 2 Unknown
NCT00006472 2020-08-18
Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
Medstar Health Research Institute
Phase 2 Terminated
NCT03087864 2020-05-11
PERFECT
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 2 Completed